• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Extract 对体外和体内破骨细胞生成的影响。

Effect of Extract on Osteoclastogenesis In Vitro and In Vivo.

机构信息

Gwangju Center, Korea Basic Science Institute (KBSI), Gwangju 61751, Republic of Korea.

Department of Seafood Science and Technology, The Institute of Marine Industry, Gyeongsang National University, Tongyeong 53064, Republic of Korea.

出版信息

Mar Drugs. 2024 Mar 20;22(3):137. doi: 10.3390/md22030137.

DOI:10.3390/md22030137
PMID:38535478
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10971717/
Abstract

We demonstrated the effect of extract (IOE) on the receptor activator of nuclear factor-κB ligand (RANKL)-promoted osteoclastogenesis in RAW 264.7 cells and confirmed that IOE inhibited RANKL-induced tartrate-resistant acid phosphatase (TRAP) activity and osteoclast differentiation. IOE inhibited protein expression of TRAP, metallopeptidase-9 (MMP-9), the calcitonin receptor (CTR), and cathepsin K (CTK). IOE treatment suppressed the expression of activated T cell cytoplasmic 1 and activator protein-1, thus controlling the expression of osteoclast-related factors. Moreover, IOE significantly reduced RANKL-phosphorylated extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK). It also reduced the RANKL-induced phosphorylation of NF-κB and nuclear translocation of p65. IOE inhibited Dex-induced bone loss and osteoclast-related gene expression in zebrafish larvae. HPLC analysis shows that IOE consists of 3.13% and 3.42% DPHC and IPA, respectively. Our results show that IOE has inhibitory effects on osteoclastogenesis in vitro and in vivo and is a potential therapeutic for osteoporosis.

摘要

我们证明了提取物（IOE）对 RAW 264.7 细胞中核因子-κB 受体激活剂配体（RANKL）促进的破骨细胞形成的影响，并证实 IOE 抑制了 RANKL 诱导的抗酒石酸酸性磷酸酶（TRAP）活性和破骨细胞分化。IOE 抑制了 TRAP、金属蛋白酶-9（MMP-9）、降钙素受体（CTR）和组织蛋白酶 K（CTK）的蛋白表达。IOE 处理抑制了活化 T 细胞细胞质 1 和激活蛋白-1 的表达，从而控制了破骨细胞相关因子的表达。此外，IOE 显著降低了 RANKL 磷酸化细胞外信号调节激酶（ERK）和 c-Jun N 末端激酶（JNK）。它还降低了 RANKL 诱导的 NF-κB 磷酸化和 p65 的核转位。IOE 抑制了 Dex 诱导的斑马鱼幼虫骨丢失和破骨细胞相关基因表达。HPLC 分析表明，IOE 分别由 3.13%和 3.42%的 DPHC 和 IPA 组成。我们的结果表明，IOE 对体外和体内的破骨细胞形成具有抑制作用，是治疗骨质疏松症的潜在药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/6219469a62ac/marinedrugs-22-00137-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/28b0150220eb/marinedrugs-22-00137-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/bed6535a1273/marinedrugs-22-00137-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/211882445fee/marinedrugs-22-00137-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/16a752937964/marinedrugs-22-00137-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/d1772d4f131d/marinedrugs-22-00137-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/602506edd4d2/marinedrugs-22-00137-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/e9ef93809876/marinedrugs-22-00137-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/4b9913335508/marinedrugs-22-00137-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/6219469a62ac/marinedrugs-22-00137-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/28b0150220eb/marinedrugs-22-00137-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/bed6535a1273/marinedrugs-22-00137-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/211882445fee/marinedrugs-22-00137-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/16a752937964/marinedrugs-22-00137-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/d1772d4f131d/marinedrugs-22-00137-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/602506edd4d2/marinedrugs-22-00137-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/e9ef93809876/marinedrugs-22-00137-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/4b9913335508/marinedrugs-22-00137-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9644/10971717/6219469a62ac/marinedrugs-22-00137-g009.jpg

相似文献

1
Effect of Extract on Osteoclastogenesis In Vitro and In Vivo.Extract 对体外和体内破骨细胞生成的影响。
Mar Drugs. 2024 Mar 20;22(3):137. doi: 10.3390/md22030137.
2
Effect of Ishophloroglucin A Isolated from on In Vitro Osteoclastogenesis and Osteoblastogenesis.从 中分离得到的异佛手柑内酯对体外破骨细胞和成骨细胞的影响。
Mar Drugs. 2023 Jun 26;21(7):377. doi: 10.3390/md21070377.
3
Rosavin suppresses osteoclastogenesis and by blocking the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways.迷迭香酸通过阻断活化B细胞核因子κB（NF-κB）和丝裂原活化蛋白激酶（MAPK）信号通路来抑制破骨细胞生成。
Ann Transl Med. 2021 Mar;9(5):383. doi: 10.21037/atm-20-4255.
4
Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.咖啡酸 3,4-二羟基苯乙基酯通过抑制丝裂原活化蛋白激酶/激活蛋白 1 和 Ca2+-活化 T 细胞胞浆 1 信号通路抑制核因子 κB 配体诱导的破骨细胞生成，预防卵巢切除诱导的骨丢失。
J Bone Miner Res. 2012 Jun;27(6):1298-1308. doi: 10.1002/jbmr.1576.
5
Diphlorethohydroxycarmalol from Ishige okamurae Suppresses Osteoclast Differentiation by Downregulating the NF-κB Signaling Pathway.来自石莼 okamurae 的二氢愈创木酸通过下调 NF-κB 信号通路抑制破骨细胞分化。
Int J Mol Sci. 2017 Dec 6;18(12):2635. doi: 10.3390/ijms18122635.
6
Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.白杨素 A 通过抑制 NF-κB 和 Akt 通路抑制 RANKL 诱导的破骨细胞生成和卵巢切除诱导的骨质疏松症。
J Ethnopharmacol. 2021 Aug 10;276:114176. doi: 10.1016/j.jep.2021.114176. Epub 2021 Apr 30.
7
12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.12-O-十四酰佛波醇-13-乙酸酯（TPA）通过抑制RANKL诱导的NF-κB活化来抑制破骨细胞生成。
J Bone Miner Res. 2003 Dec;18(12):2159-68. doi: 10.1359/jbmr.2003.18.12.2159.
8
Palmitoleic Acid Inhibits RANKL-Induced Osteoclastogenesis and Bone Resorption by Suppressing NF-κB and MAPK Signalling Pathways.棕榈油酸通过抑制NF-κB和MAPK信号通路来抑制RANKL诱导的破骨细胞生成和骨吸收。
Nutrients. 2017 Apr 28;9(5):441. doi: 10.3390/nu9050441.
9
Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.新藤黄酸通过抑制小鼠骨髓来源的单核/巨噬细胞中的 JNK 和 NF-κB 通路抑制核因子 κB 受体激活剂配体 (RANKL)诱导的破骨细胞生成。
Med Sci Monit. 2018 Apr 26;24:2569-2577. doi: 10.12659/MSM.909651.
10
Calcium-containing crystals enhance receptor activator of nuclear factor κB ligand/macrophage colony-stimulating factor-mediated osteoclastogenesis via extracellular-signal-regulated kinase and p38 pathways.含钙晶体通过细胞外信号调节激酶和p38信号通路增强核因子κB受体激活剂/巨噬细胞集落刺激因子介导的破骨细胞生成。
Rheumatology (Oxford). 2015 Oct;54(10):1913-22. doi: 10.1093/rheumatology/kev107. Epub 2015 May 20.

本文引用的文献

1
Effect of Ishophloroglucin A Isolated from on In Vitro Osteoclastogenesis and Osteoblastogenesis.从 中分离得到的异佛手柑内酯对体外破骨细胞和成骨细胞的影响。
Mar Drugs. 2023 Jun 26;21(7):377. doi: 10.3390/md21070377.
2
Attenuates Neuroinflammation and Cognitive Deficits in Mice Intracerebroventricularly Injected with LPS via Regulating TLR-4/MyD88-Dependent Pathways.通过调节TLR-4/MyD88依赖途径减轻脑室内注射LPS小鼠的神经炎症和认知缺陷。
Antioxidants (Basel). 2022 Dec 29;12(1):78. doi: 10.3390/antiox12010078.
3
RANKL biology.RANKL 生物学。
Bone. 2022 Jun;159:116353. doi: 10.1016/j.bone.2022.116353. Epub 2022 Feb 16.
4
A Glance at the Use of Glucocorticoids in Rare Inflammatory and Autoimmune Diseases: Still an Indispensable Pharmacological Tool?罕见炎症性和自身免疫性疾病中糖皮质激素的应用一瞥：仍是不可或缺的药理学工具？
Front Immunol. 2021 Jan 21;11:613435. doi: 10.3389/fimmu.2020.613435. eCollection 2020.
5
Extract Inhibits LPS-Triggered Inflammation Markers and Suppresses RANKL-Induced Osteoclastogenesis in RAW264.7.提取物可抑制脂多糖触发的炎症标志物，并抑制RAW264.7细胞中核因子κB受体活化因子配体诱导的破骨细胞生成。
Front Pharmacol. 2021 Jan 22;11:593829. doi: 10.3389/fphar.2020.593829. eCollection 2020.
6
Aqueous extract of Chrysanthemum morifolium Ramat. inhibits RANKL-induced osteoclast differentiation by suppressing the c-fos/NFATc1 pathway.菊花水提物通过抑制 c-fos/NFATc1 通路抑制 RANKL 诱导的破骨细胞分化。
Arch Oral Biol. 2021 Feb;122:105029. doi: 10.1016/j.archoralbio.2020.105029. Epub 2020 Dec 31.
7
Oral Treatment With Bisphosphonates of Osteoporosis Does Not Increase the Risk of Severe Gastrointestinal Side Effects: A Meta-Analysis of Randomized Controlled Trials.口服双膦酸盐治疗骨质疏松症不会增加严重胃肠道副作用的风险：一项随机对照试验的荟萃分析。
Front Endocrinol (Lausanne). 2020 Nov 10;11:573976. doi: 10.3389/fendo.2020.573976. eCollection 2020.
8
Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.鞣花酸通过抑制 RANK 信号通路阻断 RANKL-RANK 相互作用并抑制 RANKL 诱导的破骨细胞生成。
Chem Biol Interact. 2020 Nov 1;331:109235. doi: 10.1016/j.cbi.2020.109235. Epub 2020 Sep 21.
9
Isoliquiritigenin Derivatives Inhibit RANKL-Induced Osteoclastogenesis by Regulating p38 and NF-κB Activation in RAW 264.7 Cells.异甘草素衍生物通过调节 RAW 264.7 细胞中 p38 和 NF-κB 的激活来抑制 RANKL 诱导的破骨细胞分化。
Molecules. 2020 Aug 27;25(17):3908. doi: 10.3390/molecules25173908.
10
Bone Cell Communication Factors Provide a New Therapeutic Strategy for Osteoporosis.骨细胞通讯因子为骨质疏松症提供了一种新的治疗策略。
Chonnam Med J. 2020 May;56(2):94-98. doi: 10.4068/cmj.2020.56.2.94. Epub 2020 May 25.